NO2702992T3 - - Google Patents

Info

Publication number
NO2702992T3
NO2702992T3 NO12842668A NO12842668A NO2702992T3 NO 2702992 T3 NO2702992 T3 NO 2702992T3 NO 12842668 A NO12842668 A NO 12842668A NO 12842668 A NO12842668 A NO 12842668A NO 2702992 T3 NO2702992 T3 NO 2702992T3
Authority
NO
Norway
Application number
NO12842668A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2702992T3 publication Critical patent/NO2702992T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO12842668A 2011-10-19 2012-10-18 NO2702992T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201101158A ES2384798B1 (es) 2011-10-19 2011-10-19 Uso de melatonina para el tratamiento y/o prevención de la mucositis.
PCT/ES2012/070728 WO2013057354A1 (es) 2011-10-19 2012-10-18 Uso de melatonina para el tratamiento y/o prevención de la mucositis

Publications (1)

Publication Number Publication Date
NO2702992T3 true NO2702992T3 (de) 2018-02-24

Family

ID=46319983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12842668A NO2702992T3 (de) 2011-10-19 2012-10-18

Country Status (20)

Country Link
US (1) US8962673B2 (de)
EP (1) EP2702992B1 (de)
JP (1) JP6038933B2 (de)
CN (1) CN103945843B (de)
AU (1) AU2012324752B2 (de)
BR (1) BR112014009456B1 (de)
CA (1) CA2851754C (de)
DK (1) DK2702992T3 (de)
ES (2) ES2384798B1 (de)
HR (1) HRP20171698T1 (de)
HU (1) HUE035867T2 (de)
LT (1) LT2702992T (de)
MX (1) MX342976B (de)
NO (1) NO2702992T3 (de)
PL (1) PL2702992T3 (de)
PT (1) PT2702992T (de)
RS (1) RS56568B1 (de)
RU (1) RU2600446C2 (de)
SI (1) SI2702992T1 (de)
WO (1) WO2013057354A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2974725A1 (de) 2014-07-16 2016-01-20 Luca D'Alfonso Pharmazeutische zusammensetzung
WO2016077467A1 (en) * 2014-11-11 2016-05-19 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
EP3265070B1 (de) * 2015-03-06 2019-07-03 Repoceuticals ApS Melatonin zur vorbeugung und behandlung von strahlungsvaginitis und strahlungsproktitis
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
ITUA20164065A1 (it) * 2016-06-01 2017-12-01 Probiotical Spa Composizioni in gel per applicazioni topiche a base di batteri, preparazione delle stesse e loro usi.
ES2684408B1 (es) * 2017-03-31 2019-07-09 Univ Granada Uso de melatonina para el tratamiento de tumores
EP3844146B1 (de) * 2018-08-28 2022-09-07 Perpetuum Ventures NV Medikament mit sulforaphan-melatonin-like-verbindung
WO2024020553A2 (en) * 2022-07-22 2024-01-25 Celmatix Inc. Compositions and methods for peripheral targeting of melatonin receptor agonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006779A1 (en) * 1995-08-11 1997-02-27 Kistler Gonzague S Protection from ultraviolet (uv) radiation-induced skin damage by topical treatment with melatonin (n-acetyl-5-metroxytryptamine)
FR2754454B1 (fr) * 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
FR2795323B1 (fr) * 1999-06-23 2001-11-16 Adir Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal
WO2003024391A2 (en) 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
WO2003088986A1 (en) * 2002-04-16 2003-10-30 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
ITLO20060004A1 (it) 2006-08-08 2008-02-09 River Pharma Srl "lapille" e una nuova invenzione avente per oggetto una nuova combinazione chimica stabile per uso cosmetico e farmaceutico contenente come ingredienti attivi l'acido alfa-lipoico ed il dimetilsulfossido, in grado di migliorare l'assorbimento, la bio
EP2143451A1 (de) 2008-07-11 2010-01-13 Nobel Biocare Services AG Knochenimplantat-Anwendung
WO2010062153A1 (es) 2008-11-27 2010-06-03 GARCÍA PÉREZ, Miguel, Ángel Composiciones farmacéuticas que contienen melatonina para tratar quemadura en tejidos y órganos internos causadas por sustancias corrosivas
WO2010118461A1 (en) 2009-04-14 2010-10-21 Thierry Vancaillie Gel compositions for administration of pharmaceutically active compounds
US20110237563A1 (en) 2010-03-23 2011-09-29 Dominique Costantini Fast dissolving drug delivery systems

Also Published As

Publication number Publication date
EP2702992B1 (de) 2017-09-27
PL2702992T3 (pl) 2018-02-28
AU2012324752B2 (en) 2016-11-17
WO2013057354A1 (es) 2013-04-25
EP2702992A4 (de) 2014-06-11
RS56568B1 (sr) 2018-02-28
CA2851754A1 (en) 2013-04-25
BR112014009456A2 (pt) 2017-04-25
CA2851754C (en) 2019-03-05
US8962673B2 (en) 2015-02-24
PT2702992T (pt) 2017-11-30
LT2702992T (lt) 2017-11-27
BR112014009456B1 (pt) 2020-06-30
ES2384798A1 (es) 2012-07-12
DK2702992T3 (da) 2017-11-20
HRP20171698T1 (hr) 2017-12-29
SI2702992T1 (en) 2018-01-31
CN103945843A (zh) 2014-07-23
US20140243384A1 (en) 2014-08-28
AU2012324752A1 (en) 2014-05-01
EP2702992A1 (de) 2014-03-05
ES2647316T3 (es) 2017-12-20
CN103945843B (zh) 2016-06-29
JP2014530844A (ja) 2014-11-20
ES2384798B1 (es) 2013-06-04
MX2014004631A (es) 2015-04-14
HUE035867T2 (en) 2018-05-28
JP6038933B2 (ja) 2016-12-07
MX342976B (es) 2016-10-19
RU2014119858A (ru) 2015-11-27
RU2600446C2 (ru) 2016-10-20

Similar Documents

Publication Publication Date Title
BR112013022641A2 (de)
AP3853A (de)
BR112013031251A2 (de)
BR112013027245A2 (de)
BR112013024383A2 (de)
BR112013026905A2 (de)
BR112013023185A2 (de)
BR112013022995A2 (de)
BR112013027830A2 (de)
BR112013026744A2 (de)
BR112013023927A2 (de)
BR112013024365A2 (de)
BR112013028733A2 (de)
BR112013027121A2 (de)
BR112013027452A2 (de)
BR112013031556A2 (de)
BR112013024588A2 (de)
BR112013026790A2 (de)
BR112013032377A2 (de)
BR112013032380A2 (de)
BR112013032366A2 (de)
BR112013026895A2 (de)
BR112013018949A2 (de)
BR112013027836A2 (de)
BR112013027761A2 (de)